Legend Biotech Corp
Ownership
Ownership Structure
Who owns Legend Biotech Corp (LEGN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 46.6% of the shares are freely tradable; institutional investors hold 53.7%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 13.21 | 25,696,740 | +5.9 | 03/31/2026 |
| Deerfield Management Co | 3.95 | 7,687,638 | +29.6 | 03/31/2026 |
| Suvretta Capital Management, LLC | 3.90 | 7,581,029 | +14.7 | 03/31/2026 |
| Hillhouse Capital Advisors, Ltd. | 3.08 | 5,984,550 | +0.0 | 06/30/2026 |
| BlackRock Inc | 2.41 | 4,684,543 | +9.5 | 03/31/2026 |
| Westfield Capital Management Company, L.P. | 2.28 | 4,430,063 | -23.1 | 06/30/2026 |
| Point72 Asset Management, L.P. | 2.00 | 3,886,017 | +39.5 | 03/31/2026 |
| Kynam Capital Management, LP | 1.54 | 3,001,205 | +90.4 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity OTC | 1.91 | 3,709,610 | +0.0 | 07/31/2026 |
| Fidelity Select Pharmaceuticals Port | 1.29 | 2,514,400 | +0.2 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Zhang Ingrid | Chief Executive Officer | 1,131,860 | 21,278,968 $ | Sep 15, 2026 | direct |
| Ji Darren Xiaohui | Director | 92,103 | 1,731,536 $ | Sep 24, 2026 | direct |
| Sanders Corazon (Corsee) D. | Director | 80,101 | 1,505,899 $ | Sep 24, 2026 | direct |
| Casey Patrick John | Director | 69,590 | 1,308,292 $ | Sep 24, 2026 | direct |
| Mao Li | Director | 65,316 | 1,227,941 $ | Sep 24, 2026 | direct |
| Salovey Peter | Director | 55,096 | 1,035,805 $ | Sep 24, 2026 | direct |
| Heyman Tomas J. | Director | 53,720 | 1,009,936 $ | Sep 24, 2026 | direct |
| Bash Alan | Interim CEO | 35,142 | 660,670 $ | Aug 14, 2026 | direct |
| Santos Carlos E | Chief Financial Officer | 14,246 | 267,825 $ | Sep 21, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 24, 2026 | Mao Li | Director | Other | 20,986 | 0.00 | – |
| Sep 24, 2026 | Salovey Peter | Director | Other | 28,330 | 0.00 | – |
| Sep 24, 2026 | Casey Patrick John | Director | Other | 20,986 | 0.00 | – |
| Sep 24, 2026 | Ji Darren Xiaohui | Director | Other | 28,330 | 0.00 | – |
| Sep 24, 2026 | Heyman Tomas J. | Director | Other | 20,986 | 0.00 | – |
| Sep 24, 2026 | Sanders Corazon (Corsee) D. | Director | Other | 20,986 | 0.00 | – |
| Sep 21, 2026 | Santos Carlos E | Chief Financial Officer | Sell | 5,430 | 9.14 | 49,630 |
| Sep 21, 2026 | Santos Carlos E | Chief Financial Officer | Other | 19,676 | 0.00 | – |
| Sep 15, 2026 | Zhang Ingrid | Chief Executive Officer | Other | 1,131,860 | 0.00 | – |
| Aug 14, 2026 | Bash Alan | Interim CEO | Other | 4,908 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.